Literature DB >> 2802042

Natural killer cells and metastases from pharyngeal carcinoma.

S P Schantz1, H E Savage, T Racz, D L Taylor, P G Sacks.   

Abstract

Natural killer cell activity was assessed in 100 previously untreated pharyngeal carcinoma patients. Diminished natural killer cell function in these patients was associated with an increased risk of death from uncontrolled regional and distant metastases. During the assessment, the cell line MDA686-Ln was established from a metastatic pharyngeal carcinoma of a patient with low natural killer cell cytotoxicity. The initially cytotoxicity-resistant cell line could be lysed when natural killer cell cytotoxicity was enhanced in vitro either through enrichment of a Leu 19+ natural killer cell population by fluorescent-activated cell sorting or by interleukin-2 activation. Additionally, increased circulating immune complexes were identified in these patients, subsequently isolated, and found to block natural killer cell reactivity against MDA686-Ln. In light of this negative interaction, 38 patients were randomly evaluated for both circulating immune complex levels and natural killer cell function. Both parameters examined together were complementary in defining the risk of death with disease; four of five deaths occurred in patients with both high circulating immune complex levels and low natural killer cell function. Results support the biologic modification of natural killer cell activity for controlling metastatic pharyngeal carcinoma and point to the potential confounding influence of circulating immune complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802042     DOI: 10.1016/0002-9610(89)90134-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  13 in total

Review 1.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 2.  Innate lymphoid cells: A potential link between microbiota and immune responses against cancer.

Authors:  Santosh K Panda; Marco Colonna
Journal:  Semin Immunol       Date:  2019-03-20       Impact factor: 11.130

Review 3.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

4.  Bringing natural killer cells to the clinic.

Authors:  Laura Chiossone; Eric Vivier
Journal:  J Exp Med       Date:  2022-09-06       Impact factor: 17.579

Review 5.  Targeting natural killer cells in solid tumors.

Authors:  Guillaume Habif; Adeline Crinier; Pascale André; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Cell Mol Immunol       Date:  2019-03-25       Impact factor: 11.530

Review 6.  Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology?

Authors:  Robert W Lentz; Meryl D Colton; Siddhartha S Mitra; Wells A Messersmith
Journal:  Mol Cancer Ther       Date:  2021-04-13       Impact factor: 6.009

7.  Correlation Between Natural Killer Cell Activity and Systemic Inflammatory Markers for Heterogeneous Cancer Patients Treated With Wheel Balance Cancer Therapy.

Authors:  Hwi-Joong Kang; Kyeore Bae; Jee-Hye Kim; Chong-Kwan Cho; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2017-07-17       Impact factor: 3.279

Review 8.  Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.

Authors:  Ombretta Melaiu; Valeria Lucarini; Loredana Cifaldi; Doriana Fruci
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561

Review 9.  The Immune Endocannabinoid System of the Tumor Microenvironment.

Authors:  Melanie Kienzl; Julia Kargl; Rudolf Schicho
Journal:  Int J Mol Sci       Date:  2020-11-25       Impact factor: 5.923

10.  CAM and NK Cells.

Authors:  Kazuyoshi Takeda; Ko Okumura
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.